To explore the effects and a possible therapeutic role for CK2 inactivation in the treatment of such lymphoid malignancies, CX-4945 was used in in vitro cell viability assays and WB analysis of the phosphorylation of CK2 target site on NF-κB RelA and CDC37, demonstrating that CX-4945 is highly effective in inducing cell growth arrest of GCB and non-GCB type DLBCL as well as BL cell lines and in inhibiting CK2 kinase activity directed towards pivotal signaling molecules. Here, NFKB1 is linked to Burkitt lymphoma.